BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 22410752)

  • 21. Ex vivo expansion of highly purified NK cells for immunotherapy after haploidentical stem cell transplantation in children.
    Koehl U; Esser R; Zimmermann S; Tonn T; Kotchetkov R; Bartling T; Sörensen J; Grüttner HP; Bader P; Seifried E; Martin H; Lang P; Passweg JR; Klingebiel T; Schwabe D
    Klin Padiatr; 2005; 217(6):345-50. PubMed ID: 16307421
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Related HLA-mismatched/haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: observations of a single Chinese center.
    Huang X; Liu D
    Clin Transpl; 2011; ():237-45. PubMed ID: 22755417
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dendritic cell recovery after allogeneic stem-cell transplantation in acute leukemia: correlations with clinical and transplant characteristics.
    Porta MD; Rigolin GM; Alessandrino EP; Maiocchi M; Malcovati L; Vanelli L; Baratè C; Rumi E; Ciccone M; Cuneo A; Lazzarino M; Castoldi G
    Eur J Haematol; 2004 Jan; 72(1):18-25. PubMed ID: 14962258
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immune Reconstitution and Infection Patterns after Early Alemtuzumab and Reduced Intensity Transplantation for Nonmalignant Disorders in Pediatric Patients.
    Bhatt ST; Bednarski JJ; Berg J; Trinkaus K; Murray L; Hayashi R; Schulz G; Hente M; Grimley M; Chan KW; Kamani N; Jacobsohn D; Nieder M; Hale G; Yu L; Adams R; Dalal J; Pulsipher MA; Haut P; Chaudhury S; Davis J; Jaroscak J; Andreansky M; Willert J; Shenoy S
    Biol Blood Marrow Transplant; 2019 Mar; 25(3):556-561. PubMed ID: 30321596
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protective conditioning against GVHD and graft rejection after combined organ and hematopoietic cell transplantation.
    Strober S
    Blood Cells Mol Dis; 2008; 40(1):48-54. PubMed ID: 17827036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rapid natural killer cell recovery determines outcome after T-cell-depleted HLA-identical stem cell transplantation in patients with myeloid leukemias but not with acute lymphoblastic leukemia.
    Savani BN; Mielke S; Adams S; Uribe M; Rezvani K; Yong AS; Zeilah J; Kurlander R; Srinivasan R; Childs R; Hensel N; Barrett AJ
    Leukemia; 2007 Oct; 21(10):2145-52. PubMed ID: 17673900
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Expanded donor natural killer cell and IL-2, IL-15 treatment efficacy in allogeneic hematopoietic stem cell transplantation.
    Chen G; Wu D; Wang Y; Cen J; Feng Y; Sun A; Tang X; Chang H; Zhu Z
    Eur J Haematol; 2008 Sep; 81(3):226-35. PubMed ID: 18573173
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Busulfan, fludarabine, and alemtuzumab as a reduced toxicity regimen for children with malignant and nonmalignant diseases improves engraftment and graft-versus-host disease without delaying immune reconstitution.
    Law J; Cowan MJ; Dvorak CC; Musick L; Long-Boyle JR; Baxter-Lowe LA; Horn B
    Biol Blood Marrow Transplant; 2012 Nov; 18(11):1656-63. PubMed ID: 22609040
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Association of natural killer cells in allografts with transplant outcomes in patients receiving G-CSF-mobilized PBSC grafts and G-CSF-primed BM grafts from HLA-haploidentical donors.
    Zhao XY; Chang YJ; Xu LP; Liu DH; Liu KY; Huang XJ
    Bone Marrow Transplant; 2009 Dec; 44(11):721-8. PubMed ID: 19377516
    [TBL] [Abstract][Full Text] [Related]  

  • 30. KIR haplotype B donors but not KIR-ligand mismatch result in a reduced incidence of relapse after haploidentical transplantation using reduced intensity conditioning and CD3/CD19-depleted grafts.
    Michaelis SU; Mezger M; Bornhäuser M; Trenschel R; Stuhler G; Federmann B; Oevermann L; Kanz L; Handgretinger R; Bethge WA
    Ann Hematol; 2014 Sep; 93(9):1579-86. PubMed ID: 24771045
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Alternative donor: αß/CD19 T-cell-depleted haploidentical hematopoietic stem cell transplantation for sickle cell disease.
    Foell J; Kleinschmidt K; Jakob M; Troeger A; Corbacioglu S
    Hematol Oncol Stem Cell Ther; 2020 Jun; 13(2):98-105. PubMed ID: 32202248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Early recovery of natural killer cells post T-cell depleted allogeneic stem cell transplantation using alemtuzumab "in the bag".
    Davison GM; Opie JJ; Davids SFG; Mohammed R; Novitzky N
    Transpl Immunol; 2024 Jun; 84():102045. PubMed ID: 38641148
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immunological reconstitution and correlation of circulating serum inflammatory mediators/cytokines with the incidence of acute graft-versus-host disease during the first 100 days following unrelated umbilical cord blood transplantation.
    Abu-Ghosh A; Goldman S; Slone V; van de Ven C; Suen Y; Murphy L; Sender L; Cairo M
    Bone Marrow Transplant; 1999 Sep; 24(5):535-44. PubMed ID: 10482939
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Feasibility of an outpatient HLA haploidentical stem cell transplantation program in children using a reduced-intensity conditioning regimen and CD3-CD19 depletion.
    González-Llano O; Rodríguez-Romo LN; Mancías-Guerra Mdel C; Tarín-Arzaga L; Jaime-Pérez JC; Herrera-Garza JL; Cantú-Rodríguez OG; Gutiérrez-Aguirre CH; García-Sepúlveda RD; García-Marín AY; Villarreal-Martínez L; Salazar-Riojas Mdel R; Gómez-Almaguer D
    Hematology; 2014 Jan; 19(1):10-7. PubMed ID: 23601986
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Haploidentical Stem Cell Transplantation in Children With Hematological Malignancies Using αβ
    Diaz MA; Zubicaray J; Molina B; Abad L; Castillo A; Sebastian E; Galvez E; Ruiz J; Vicario JL; Ramirez M; Sevilla J; González-Vicent M
    Front Immunol; 2019; 10():2504. PubMed ID: 31736949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hematopoietic stem cell transplantation from alternative sources in adults with high-risk acute leukemia.
    Aversa F; Reisner Y; Martelli MF
    Blood Cells Mol Dis; 2004; 33(3):294-302. PubMed ID: 15528148
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Dose-reduced conditioning and allogeneic hematopoietic stem cell transplantation from unrelated donors in 42 patients.
    Bornhäuser M; Thiede C; Platzbecker U; Jenke A; Helwig A; Plettig R; Freiberg-Richter J; Röllig C; Geissler G; Lutterbeck K; Oelschlagel U; Ehninger G
    Clin Cancer Res; 2001 Aug; 7(8):2254-62. PubMed ID: 11489799
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Assessment of immune reconstitution status in recipients of a successful hematopoietic stem cell transplant from peripheral blood after reduced intensity conditioning.
    Jaime-Pérez JC; Villarreal-Villarreal CD; Méndez-Ramírez N; Vázquez-Garza E; Salazar-Riojas R; Gómez-Almaguer D
    Blood Cells Mol Dis; 2016 May; 58():52-6. PubMed ID: 27067489
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Prediction of T-cell immune reconstitution by investigating T cell receptor excision circle and T-cell receptor beta-chain variable region clonal repertoire in leukemia patients after allogeneic hematopoietic stem cell transplantation].
    Fu YW; Wu DP; Cen JN; Feng YF; Chang WR; Qiu QC; Zhu ZL; Zhu P
    Zhonghua Yi Xue Za Zhi; 2007 Aug; 87(32):2265-7. PubMed ID: 18001548
    [TBL] [Abstract][Full Text] [Related]  

  • 40. T-cell receptor Vbeta repertoire after myeloablative and reduced intensity conditioning allogeneic haematopoietic stem cell transplantation.
    Hentschke P; Omazic B; Mattsson J; Näsman-Björk I; Lundkvist I; Gigliotti D; Barkholt L; Ringdén O; Remberger M
    Scand J Immunol; 2005 Mar; 61(3):285-94. PubMed ID: 15787747
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.